Efficacy and safety of cyclosporine and steroid for the treatment of minimal change nephrotic syndrome

Efficacy and safety of cyclosporine and steroid for the treatment of minimal change nephrotic syndrome - Cyclosporine for MCNS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000963

Enrollment

Registered

2010-01-01

Start date

2007-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Minimal change nephrotic syndrome

Interventions

administration of cyclosporine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: MCNS patients proven by renal biopsy

Exclusion criteria

Exclusion criteria: Cr>=2.0mg/dl or eGFR<50 Malignancy Uncontrolled hypertension Seizure disorder Pregnant women Infection Severe cardiac, hepatic or pancreatic disease Alelrgy to cyclosporine

Design outcomes

Primary

Measure	Time frame
Rate for complete remission Total dose of steroid Duration of admission	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026